뉴스 이미지
400 x 250
400 x 250
차백신연구소와 mRNA 백신·치료제 공동개발 MOU 체결
SML바이오팜과 차백신연구소가 mRNA 기반 백신 및 치료제 공동개발을 위한 포괄적 업무협약을 체결했습니다.
Hero Background Image
1920 x 1080
1920 x 1080
mRNA Platform Technology
Pioneering the Future of
Disease Treatment
SML Biopharm develops personalized cancer vaccines and infectious disease therapeutics based on differentiated mRNA·LNP platform technology.
Scroll Down
0
Founded
0
Core Pipelines
0
Global Partners
0
Gov. Projects
Platform Technology
Next-Generation
View Technology Details
Next-Generation
mRNA·LNP Platform
Based on over 10 years of mRNA research experience, SML Biopharm possesses proprietary mRNA sequence design, UTR·Poly(A) optimization, and high-efficiency, low-toxicity LNP delivery technology.
Proprietary mRNA sequence design and expression platform
High-efficiency, low-toxicity LNP delivery library
MFDS-transferred LNP composition technology
Pipeline
Key Pipelines
We are developing innovative pipelines including personalized cancer vaccines and infectious disease therapeutics based on mRNA platform technology.
Cancer Vaccine
Personalized Cancer Vaccine
Various Solid Tumors
Development Stage
Preclinical
Infectious Disease
SFTS Antibody Therapeutics
Severe Fever with Thrombocytopenia Syndrome
Development Stage
Preclinical
Infectious Disease
Infectious Disease Vaccine
Emerging Infectious Diseases
Development Stage
Discovery
Latest News
View All
Latest News
뉴스 이미지
400 x 250
400 x 250
Affilogic과 mRNA-LNP 기반 표적 신약 개발 MOU 체결
프랑스 Affilogic의 Nanofitin 기술을 SML바이오팜의 mRNA-LNP 플랫폼에 접목하여 차세대 표적 치료제를 개발합니다.
뉴스 이미지
400 x 250
400 x 250
유럽 mRNA 학회 초청 연사로 참여
독일 프랑크푸르트에서 열린 4th mRNA-Based Therapeutics Summit Europe에 국내 기업 유일 초청 연사로 참여했습니다.
Global Partners
Global Partnership
We collaborate with leading companies, research institutions, and governments domestically and internationally to develop innovative therapeutics.
Cha Vaccine Institute
Probio
CATUG
Affilogic
Catholic University of Korea
KDCA
Join Our Journey
We are looking for passionate researchers to innovate future medicine with mRNA technology.